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OBJECTIVES: Minimal health-related quality of life (HRQOL) data have been pub-
lished on patients (pts) withmultiplemyeloma (MM) in the United States (US). This
analysis characterizedHRQOL of ptswith active, symptomaticMMby International
Staging System (ISS) stage and ECOG status. METHODS: Data were collected in
Connect MM®, a prospective US registry initiated in 2009. Clinicians reported on pt
demographics and clinical characteristics. Pts reported HRQOL within twomonths
of diagnosis by completing the Brief Pain Inventory (BPI), EQ-5D, and Functional
Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM) instruments. Mean
(Standard Deviation (SD)) BPI, EQ-5D and FACT-MM scores were analyzed by ISS
and ECOG. Statistical significance was ascertained by ANOVA using SAS 9.1.
RESULTS: 640 pts from 189 centers provided data. Pts were predominantly male
(56%) and white (79%) with mean age 66.9 yrs (SD 11.8). Pts were characterized by
evaluable ISS stage (Stage I (107), II (141), III (151), and ECOG status ( 0 (154), 1 (227),
2/3 (76)). Mean (SD) BPI pain was 2.7 (2.5), 3.6 (3.1), 3.9 (2.8) for ISS I, II and III
(p0.0083), and 2.4 (2.7), 3.5 (2.7), 4.5 (3.1) for ECOG 0, 1 and 2/3 (p0.0001). EQ-5D
pain/discomfort and usual activities scores were most compromised. All EQ-5D
domains increased in severity as ECOG became more advanced (p0.0001), while
mobility (p0.0033), self care (p0.0001) and usual activities (p0.0006) increased
in severity as ISS becamemore advanced. Lower FACT-MM physical (p0.0026 and
p0.0001) and functional (p0.0009 and p0.0001) scores were observed with in-
creasing ISS and ECOG severity. CONCLUSIONS: Connect MM® findings indicate
that increasing ISS and ECOG is associated with greater HRQOL degradation. In
particular, physical and functioning domains, pain, and ability to conduct usual
activities and to provide self care requires special attention from clinicians.
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BACKGROUND: Hepatocellular carcinoma (HCC) is the sixth most common cancer
and the third leading cause of cancer death worldwide. While a number of tech-
nologies are emerging, little is known about their future impact on this devastating
disease. OBJECTIVES: To explore clinicians’ views on emerging technologies with
respect to their expected impact on HCC outcomes in the next 5 to 10 years.
METHODS: We focused on 11 emerging technologies likely to impact HCC out-
comes as previously identified through qualitative research. A survey was con-
ducted with clinicians considered liver disease and liver cancer experts in Europe,
Asia and the United States. Clinicians’ views on the future impact of these tech-
nologies were explored using best-worst scaling. A balance incomplete block de-
sign (BIBD) with 11 choice tasks was constructed. Each task contained five technol-
ogies. Respondents were asked to identify those technologies that will have the
most and least likely impact on HCC outcomes within 5 to 10 years. Statistical
analysis used sequential best-worst. RESULTS: One hundred and twenty experts in
10 different countries completed the survey. Of these 41%were hepatologist and 65%
described their main area of specialty as HCC. Technologies considered to have the
most impactbyparticipants included: earlydetectionofHCC,molecular targeted ther-
apy, genetic/genomic biomarkers, hepatitis C vaccination and stem cell therapy. Ad-
juvant/Neo-adjuvant therapies, interventional radiology, biopsy-free HCC diagnos-
tics, transplant technology, improved surgical techniques and immunomodulation
were seen as the least important emerging technologies. CONCLUSIONS: This study
demonstrates that preference-based methods, such as best-worst scaling, are val-
ued tools in understanding differences in opinions about the likely impact of
emergingmedical technologies. Such information can be used by policy makers as
part of horizon scanning and as a mean to align research budgets with informed
clinicians’ expectations.
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OBJECTIVES: Empowerment is a multi-faceted construct that, in the cancer con-
text, refers to feelings of being able to manage the challenges of the disease and
gain a sense of control over the cancer experience. Empowerment is a multi-fac-
etted and difficult to measure construct, and few patient empowerment measures
exist for cancer research. We evaluated the psychometrics of the Health Education
Impact Questionnaire (heiQ) evaluation system originally developed for chronic
diseases in Australia. It has been translated into 19 languages, applied across dis-
eases, interventions and healthcare settings. Five of the original 8 scales were
considered conceptually relevant to the empowerment construct in cancer; Emo-
tional wellbeing, Constructive attitudes and approaches, Skill and technique ac-
quisition, Social integration and support, and Health services navigation.
METHODS:We recruited English-speaking Canadians diagnosed 27 months ear-
lier with different types of cancer who were randomly selected from the popula-
tion-based Manitoba Cancer Registry, and from users of the Canadian Cancer So-
ciety telephone support programs. Participants (n731) completed a mailed
questionnaire including the heiQ, other related constructs and demographic ques-
tions. Traditional psychometric analyses andmodern confirmatory factor analysis
(CFA: LISREL) were used to examine psychometric structure and construct validity.
RESULTS:Ordinal CFAwith robustmaximum likelihood estimation gave very good
model fit (2(265)528.17, RMSEA0.038, NNFI0.994, CFI0.995, SRMR0.055).
Factor loadings were moderately high (0.65-0.91). Cronbach alphas were 0.76 to
0.85. A priori hypotheses regarding the magnitude and direction of correlations
between certain heiQ scales and measures of cancer self-efficacy were supported.
CONCLUSIONS: These results provide strong evidence that the five constructs con-
ceptualized as representing key dimensions of empowerment performwell in can-
cer survivors. This is the first formal validation of the heiQ empowerment-related
dimensions in the cancer setting. These scales will fill an important gap in cancer
research and evaluation by providing validated measures of important effects of
cancer information and support interventions.
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OBJECTIVES: For localized prostate cancer, both primary androgen deprivation
therapy (PADT) and surgery is frequently used, without any comparative evidence
of survival benefit between them. This retrospective study aimed to examine the
predictors of receiving PADT versus radical prostatectomy (RP) as a monotherapy
among clinically localized prostate cancer patients.METHODS:Male veterans with
localized prostate cancer were identified from the Veterans Affairs Veterans Inte-
grated Service Network (VISN) 16 (01/2004-12/2008). Eligible patients had no other
cancer diagnosis before the first prostate cancer diagnosis and used PADT or RP as
monotherapy within 6 month after first diagnosis. A proxy variable (preference)
was created to account for potential physician influence on treatment choice in
each of the ten medical centers of VISN 16. Predictors fitted in a logistic regression
model included age, race, marital status, non-VA insurance, cancer stage, baseline
prostate specific antigen (PSA), Charlson comorbidity index (CCI), alcohol and to-
bacco use, calendar year at diagnosis, and preference. RESULTS: The analysis sam-
ple included 878 patients, 523 in PADT cohort and 355 in RP cohort. The age [Mean
(SD)] in PADT was 71.4 (8.92) years old, 60.3 (5.91) in RP, p0.001. The significant
predictors of receiving treatment of PADT over RP included being 65 years old or
over (OR9.152, 95% CI: 5.688, 14.725), higher baseline PSA (OR1.184, 95%
CI1.133, 1,237), higher CCI (CCI1: OR2.246, 95% CI1.062, 4.753; CCI2:
OR7.328, 95% CI2.599, 20.665) and preference of PADT (OR4.603, 95% CI3.068,
6.906). Other explanatory variables including race, marital status, cancer stage,
year at diagnosis were not significant (all p-values0.05). CONCLUSIONS: Among
localized prostate cancer patients in VA, age, baseline PSA and CCI were strong
predictors of treatment selection of PADT versus RP. We did not observed a signif-
icant treatment selection patterns change over time as expected.
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OBJECTIVES: The primary aim was to examine first-line systemic therapy for pa-
tients with advanced NSCLC in relation to concordance with NCCN GLs and FDA
labeling and examine the evidence supporting off-label GL concordant therapies.
METHODS: The cohort included advanced NSCLC patients initiating first-line sys-
temic therapy at one of 8 NCCN institutions from January 2007 through December
2009. GL concordance and off-label use of regimens were examined. Where incon-
sistency between drug labels was observed the more inclusive label was utilized.
For example, carboplatin has no label for NSCLC; however, bevacizumab’s label
directs use in combination with carboplatin and paclitaxel. Bevacizumab’s label
was utilized to characterize carboplatin’s on-label use. RESULTS: Excluding clinical
trial patients (n210) and patients with unknown therapies (n9), 1,121 stage
IIIB/IV patients receiving systemic therapy were identified. Patients were 63 years
old (median), with eithermanaged-care (48%) orMedicare (40%) insurance, andhad
adenocarcinoma (64%). Most had smoking histories (81%). Overall, 84% received GL
concordant therapy; 20% received therapy consistent with FDA labeling. 209 (19%)
patients received GL concordant on-label therapy, 732 (65%) received GL concor-
dant off-label therapy; 18 (2%) patients received GL non-concordant on-label ther-
apy; and 162 (14%) received GL non-concordant off-label therapy. The carboplatin-
paclitaxel-bevacizumab (n132, 63%) and cisplatin-based doublets (n72, 34%)
account for the majority of on-label GL concordant care. Carboplatin-based dou-
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